Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth-Reference-Cited by-同舟云学术

Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth

Published:2015-01-22 Issue:5 Volume:6 Page:2928-2938
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Barsotti Anthony M.¹,Ryskin Michael¹,Zhong Wenyan¹,Zhang Wei-Guo¹,Giannakou Andreas¹,Loreth Christine²,Diesl Veronica²,Follettie Maximillian¹²,Golas Jonathon¹,Lee Michelle³,Nichols Timothy³,Fan Conglin⁴,Li Gang⁴,Dann Stephen⁴,Fantin Valeria R.⁴,Arndt Kim¹,Verhelle Dominique⁴,Rollins Robert A.¹

Affiliation:

1. Oncology Research Unit, Pfizer Worldwide Research and Development, Pearl River, NY 10965, USA

2. Oncology Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA 02140, USA

3. Drug Safety Research and Development, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA

4. Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mining cancer genomes for change-of-metabolic-function mutations;Communications Biology;2023-11-10

2. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures;International Journal of Molecular Sciences;2023-07-12

3. Cancer and meiotic gene expression: Two sides of the same coin?;Current Topics in Developmental Biology;2023

4. Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression;Journal of Medicinal Chemistry;2021-10-06

5. Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma;Journal of Personalized Medicine;2021-09-09